Kindstar Globalgene Technology, Inc.

Kindstar Globalgene Technology, Inc.

HHKEX:9960
0.89
HKD
+0.00
(-0.56%)
926.33MMarket Cap
Mar 26Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.78
0.92
0.98
1.88
1.74
1.01
0.98
0.94
- -
Basic EPS, GAAP
-0.06
-0.19
-1.08
-2.93
0.09
0.04
-0.06
-0.06
- -
Free Cash Flow per Basic Share
-0.01
0.06
0.05
-0.44
-0.13
-0.2
-0.19
0.04
- -
Dividend per Share
- -
- -
0.04
0.13
- -
- -
0.03
0.02
- -
Book Value per Share
-0.69
-0.89
-2.04
3.02
3.02
2.91
2.86
2.64
2.59
Tangible Book Value per Share
-0.69
-0.9
-2.05
2.99
2.97
2.87
2.81
2.39
2.37
Basic Weighted Avg Shares
906
906
906
496
795
958
946
993
997
Sales/Revenue/Turnover
706
833
891
931
1,387
967
928
934
- -
Operating Margin (%)
2.76
6.94
10.44
4.04
5.09
-4.39
-3.92
-8.89
- -
Depreciation Expense
38
43
51
57
65
75
74
105
- -
Net Income, GAAP
-53
-170
-974
-1,454
75
41
-55
-59
- -
Effective Tax Rate (%)
- -
- -
- -
- -
7
15.87
- -
- -
- -
Profit Margin (%)
-7.46
-20.39
-109.27
-156.28
5.44
4.27
-5.89
-6.29
- -
Working Capital
-840
-989
825
2,117
1,887
1,965
1,392
1,333
1,484
LT Debt
37
26
24
10
9
29
94
230
265
Total Equity
-618
-799
-1,834
2,725
2,854
2,895
2,824
2,786
2,641
Return on Invested Capital (%)
- -
- -
- -
- -
1.05
-1.12
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
2.61
1.72
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
2.72
1.45
-1.93
-2.13
- -

Capital Structure

CNY

•

in mil. unless spec.
Jun'24
Dec'24
Jun'26
ST Debt
265
304
130
LT Borrowings
69
69
249
LT Finance Leases
29
26
16
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
979
974
996
Market Capitalization
1,366
1,080
801

Working Capital

CNY

•

in mil. unless spec.
Jun'24
Dec'24
Jun'26
Total Current Assets
2,282
2,247
2,288
Cash, Cash Equivalents & STI
1,546
1,599
1,736
Accounts Receivable, Net
660
632
557
Inventories
50
51
50
Total Current Liabilities
813
854
804
Payables & Accruals
- -
- -
- -
ST Debt
265
304
130
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-49.23%
-1.37%
Free Cash Flow
- -
-134.07%
-124.28%
Net Income, GAAP
- -
-65.15%
7.61%
Sales/Revenue/Turnover
- -
3.94%
0.65%
Total Cash Common Dividend
- -
- -
-8.63%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
928
2025
- -
- -
934
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.06
2025
- -
- -
-0.06
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.03
2025
- -
- -
0.02
2026
- -
- -
- -

Company Description

CEO
Shi Ang Huang
Full Time Employees
3,100
Sector
Health services
Industry
Medical/Nursing services
Address
Biolake D2-1 Wuhan HB China
IPO Date
Jul 16, 2021
Business
Kindstar Globalgene Technology, Inc. (9960.HK) operates as a leading provider of clinical esoteric testing services in China, offering advanced diagnostic solutions for hematology, genetic diseases and rare diseases, gynecology and maternity-related testing, infectious diseases, neurology, oncology, routine testing, scientific research services, and contract research organization services; its laboratory platforms include flow cytometry, cytogenetic analysis, medical genomics, molecular biology, hematopathology, mass spectrometry, pathology, clinical immunology, microbiology, and scientific research testing. The company delivers over 3,800 testing items, including more than 2,300 for blood system diseases such as leukemia and lymphoma, over 400 for genetic and rare diseases, 34 gynecology-related tests supported by technologies like NGS and mass spectrometry, over 200 for infectious diseases covering tuberculosis and fungal infections, over 100 for neurology conditions like autoimmune encephalitis, over 400 for oncology applications targeting lung, breast, colorectal, and other cancers, and routine biochemical, immunological, hematological, and microbiological tests. Founded in 2003 and headquartered in Wuhan with major laboratories in Beijing, Shanghai, Tianjin, Chengdu, Urumqi, and additional facilities, Kindstar Global serves over 3,000 hospitals across 31 provinces, including more than 1,000 tertiary hospitals, as well as pharmaceutical companies and research institutions. Recent developments include the January 2025 completion of the acquisition of Guangzhou AnchorDx Medical Co., Ltd. and Guangzhou Kangchengweiye Biotechnology Co., Ltd., enhancing solid tumor testing capabilities with products like PulmoSeek for lung cancer early screening and UriFind for urothelial carcinoma, both advancing in regulatory filings; angel investment in Wuhan Tuoruijing in January 2025 for ultra-multiplex PCR platforms in hematology, infectious diseases, and oncology; joint venture with U.S.-based Biostate AI in June 2025 to form Wuhan Baisheng Intelligence for AI-driven RNA multi-omics diagnostics targeting autoimmune diseases, cancers, diabetes, and transplantation; expanded stake to 40% in Huaxi Kindstar Health Technology in November 2025 via subsidiary; and over 20% growth in self-operated esoteric testing reagents sales in the first half of 2025, with new R&D projects in CAR-T monitoring, MRD detection, and immune repertoire products like Lymscan. The company listed on the Hong Kong Stock Exchange Main Board in July 2021 and maintains operations primarily in the People's Republic of China through its investment holding structure incorporated in the Cayman Islands.